MTOR and neuroblastoma: The RIST therapy, a novel multimodal treatment design for high-risk NB, is based on metronomically combining molecular-targeted biologicals, mTOR inhibitor Rapamycin and tyrosine-kinase inhibitor Dasatinib, with a conventional well-established chemotherapeutic backbone, consisting of the topoisomerase inhibitor Irinotecan and alkylator Temozolomide [14].